PL397563A1 - Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof - Google Patents
Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereofInfo
- Publication number
- PL397563A1 PL397563A1 PL397563A PL39756311A PL397563A1 PL 397563 A1 PL397563 A1 PL 397563A1 PL 397563 A PL397563 A PL 397563A PL 39756311 A PL39756311 A PL 39756311A PL 397563 A1 PL397563 A1 PL 397563A1
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical form
- tablet
- angiotensin
- losartan
- potassium
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Postac farmaceutyczna zawierajaca terapeutycznie skuteczna ilosc antagonisty receptorów typu AT1 angiotensyny II, którym jest sól potasowa losartanu, charakteryzuje sie tym, ze stanowi ja tabletka powlekana zawierajaca substancje czynna - losartan potasu, naniesiony na nosnik, którym jest laktoza jednowodna, w ilosci od 10% do 27% wagowych w stosunku do calkowitej masy tabletki, oraz stearylofumaran sodu w ilosci od 2% do 3% wagowych w stosunku do calkowitej masy tabletki jako substancje poslizgowa i inne substancje pomocnicze wybrane sposród substancji wiazacych oraz substancji dezintegrujacych. Przedmiotem wynalazku jest takze sposób wytwarzania okreslonej powyzej postaci farmaceutycznej, który polega na tym, ze losartan potasu nanosi sie na ziarna jednowodnej laktozy w procesie granulacji fluidyzacyjnej, wytworzony granulat miesza sie z substancja wiazaca, substancja dezintegrujaca oraz substancja poslizgowa, która stanowi stearylofumaran sodu. Nastepnie wytworzona mieszanine tabletkuje sie, a rdzenie tabletek powleka.The pharmaceutical form containing a therapeutically effective amount of the angiotensin II type AT1 receptor antagonist, which is losartan potassium, is characterized by being a film-coated tablet containing the active substance - potassium losartan, applied to a carrier which is lactose monohydrate, in an amount of 10% to 27% by weight relative to the total weight of the tablet, and sodium stearyl fumarate in an amount of 2% to 3% by weight relative to the total weight of the tablet as a lubricant and other excipients selected from binders and disintegrants. The invention also relates to a process for the preparation of the above-described pharmaceutical form, which consists in the fact that potassium losartan is applied to grains of lactose monohydrate in a fluidization granulation process, the resulting granules are mixed with a binder, disintegrant and glidant, which is sodium stearyl fumarate. The resulting mixture is then tableted and the tablet cores coated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
PL397563A1 true PL397563A1 (en) | 2013-07-08 |
PL218490B1 PL218490B1 (en) | 2014-12-31 |
Family
ID=48748711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL397563A PL218490B1 (en) | 2011-12-27 | 2011-12-27 | Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL218490B1 (en) |
-
2011
- 2011-12-27 PL PL397563A patent/PL218490B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL218490B1 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
MX2013008431A (en) | Mineralocorticoid receptor antagonists. | |
RS54329B1 (en) | Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections | |
PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
NZ703124A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
NZ589764A (en) | NMDA receptor antagonists for the treatment of neuropsychiatric disorders | |
UA106057C2 (en) | Normal;heading 1;heading 2;heading 3;PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUND, THEIR PHARMACEUTICAL COMPOSITION CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | |
UA115320C2 (en) | Kinase inhibitors | |
SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
MX336051B (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors. | |
MX2013012588A (en) | Kinase inhibitors. | |
MY153712A (en) | Preparation of controlled release skeletal muscle relaxant dosage forms | |
NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
MX344846B (en) | Combination of active loaded granules with additional actives. | |
NZ703152A (en) | Dosing regimen for janus kinase (jak) inhibitors | |
MX2013014577A (en) | Heteroaryl compounds as 5-ht4 receptor ligands. | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
AR100977A1 (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION | |
MY161236A (en) | (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr | |
PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
MX339858B (en) | Novel compounds as histamine h3 receptor ligands. | |
MX345544B (en) | Triazole derivatives as ligands for gaba receptors. | |
MX2014002395A (en) | Novel rock kinase inhibitors. | |
WO2010136035A3 (en) | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |